CDK2 and neuroblastoma: Although, the latter two need to be investigated, Poon et al. [43] demonstrated in a comparative study with selective CDK7, CDK9, CDK4/6 and pan CDK inhibitors that fadraciclib, a CDK2/9 inhibitor, was the most effective agent at downregulating MCL1 and MYC at growth inhibitory concentrations in neuroblastoma models.